Allopole-A|CAS 3057557-03-3 |DC Chemicals

Cas No.:	3057557-03-3
Chemical Name:	Allopole-A
Synonyms:	Allopole-A , Allopole A , AllopoleA
SMILES:	O=C(C1=C(C=C(Cl)S1)N23)N(CC4CC4)C2=NNC3=S
Formula:	C₁₁H₉ClN₄Os₂
M.Wt:	312.79
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Park JE, et al. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2305037120.

Cat. No.	Product name	Field of application
DC73220	Allopole-A	Allopole-A is the first allosteric, specfic inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1) with IC50 of 2.5 nM in FP-based assays, Allopole-A is the active form of Allopole.
DC73219	Allopole	Allopole is the first allosteric, specfic and cell-permeable inhibitor of the noncatalytic polo-box domain (PBD) of PLK1 (Polo-like kinase 1), Allopole is the prodrug of Allopole-A.
DC70300	CFI-400945	CFI-400945 is a potent, highly selective PLK4 inhibitor with Ki of 0.26 nM and IC50 of 2.8 nM, does not significantly inhibits PLK1/2/3 at 50 uM; causes dysregulated centriole duplication, mitotic defects, and cell death in multiple cancer cell lines (A549 GI50=5 nM, OVCAR-3 GI50=18 nM); significantly inhibits human cancer xenografts; causes polyploidy, growth inhibition, and apoptotic death of murine and human lung cancer cells, despite expression of mutated KRAS or p53, produces supernumerary centrosomes and mitotic defects in lung cancer cells.
DC9594	Poloxin	Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.
DC8768	HMN-214	HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.